RT Journal Article SR Electronic T1 Analysis of the association between rs111200466 variants and cervical Cancer susceptibility in Sudanese women JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.05.21250955 DO 10.1101/2021.07.05.21250955 A1 Andarawi, Safaa Othman A1 Bakheit, Sahar YR 2021 UL http://medrxiv.org/content/early/2021/07/07/2021.07.05.21250955.abstract AB Worldwide there are more than 273,000 deaths from cervical cancer each year and it accounts for 9% of female cancer deaths. The high-risk variants of human papillomavirus such as HPV 16 and 18 are major etiological agents of cervical cancer. The persistency of infection with HPV may due to inappropriate immune response due to SNPs interfering with the function of particular part of the immune system. Toll-like receptors (TLRs) play an important role in the signaling of many pathogen-related molecules and endogenous proteins associated with immune activation. The –196 to –174del polymorphism affects the TLR2 gene and alters its promoter activity.Aim In this study we investigated the presence and the influence of TLR2 –196 to – 174del polymorphism on the risk of cervical cancer development in Sudanese. The study was performed on 42 patients with cervical cancer and 27 healthy controls. Genotyping of –196 to –174del polymorphism of TLR2 was investigated using allele-specific polymerase chain reaction method in all subjects. We documented the presence of–196 to –174del polymorphism of TLR2 in Sudanese women with allele frequency 37% of control and 34% of patient sample although there was no observed association between this SNP and the risk of cervical cancer (p value. 394).Further studies are needed in a large and ethnically diverse population to determine the impact of the TLR2 polymorphism in the susceptibility of cervical cancer.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ethical committee institute of endemic diseases university of KhartoumAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data in the manuscript are available